ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

Nilotinib (Tasigna) has been approved by the FDA for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The approval is both in the frontline setting and for those with resistance or intolerance to prior therapy, including imatinib.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.